AVASTIN 400 solution for infusion 16 mll
Product Overview
AVASTIN 400mg/16ml Solution for Infusion is a targeted biologic therapy containing bevacizumab, a recombinant humanized monoclonal antibody. It is designed to inhibit angiogenesis, the formation of new blood vessels that tumors need to grow and spread. Avastin works by specifically binding to Vascular Endothelial Growth Factor (VEGF), a protein that plays a key role in stimulating blood vessel formation, thereby cutting off the blood supply to the tumor.
This prescription medication is used in combination with various chemotherapy regimens for the treatment of several types of cancer, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and certain types of ovarian cancer. Its mechanism of action helps to slow tumor growth and progression, improving outcomes for patients.
Benefits of Use
- Targets and inhibits the growth of new blood vessels that feed tumors.
- Slows tumor growth and progression in various advanced cancers.
- Used in combination with chemotherapy to enhance treatment efficacy.
- Can improve progression-free survival and overall survival in eligible patients.
How to Use
- AVASTIN is administered as an intravenous infusion by a healthcare professional in a clinical setting.
- The specific dose and duration of treatment will be determined by your doctor based on your type of cancer, body weight, and response to treatment.
- The solution must be diluted with sodium chloride 9 mg/mL (0.9%) solution for injection before infusion.
- Infusions typically last between 30 to 90 minutes.
- Regular monitoring by your healthcare team is essential during treatment.
Caution & Warnings
- AVASTIN is a prescription-only medication and must only be administered under the supervision of a physician experienced in the use of antineoplastic agents.
- Risk of gastrointestinal perforation and fistula formation.
- May cause serious bleeding or hemorrhage.
- Increased risk of arterial and venous thromboembolic events (e.g., stroke, heart attack, blood clots).
- Can impair wound healing; treatment may be temporarily or permanently discontinued before or after surgery.
- Risk of proteinuria and nephrotic syndrome.
- May cause hypertension (high blood pressure) which should be monitored and managed.
- Rare but serious allergic or infusion-related reactions can occur.
- Not recommended for use during pregnancy or breastfeeding due to potential fetal harm. Effective contraception should be used during treatment and for a period after the last dose.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs, supplements, and herbal remedies.
Ingredients
Active Ingredient: Bevacizumab (400 mg per 16 mL vial, equivalent to 25 mg/mL)
Excipients: Alpha,alpha-trehalose dihydrate, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, polysorbate 20, water for injection.
Product Details
- Form: Solution for infusion
- Strength: 400 mg/16 mL (25 mg/mL)
- Manufacturer: F. Hoffmann-La Roche Ltd (Roche)
- Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the vial in the outer carton to protect from light.
- Legal Status: Prescription Only Medicine (POM)
| Gtin | 270-24-14 |
|---|---|
| Recommended Sale Price | 4271.4 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | Bevacizumab |
| SFDA Reg. No | 270-24-14 |
| IBC | 270-24-14 |
| Drug Type | Prescription Only Medicine (POM) |
| Scientific Name | Bevacizumab |
| Strength | 400 |
| Strength Unit | mg |
| Form | Solution for infusion |
| Admin Route | Intravenous |
| Size | 16 |
| Size Unit | mL |
| Package Types | Vial |
| Package Size | 1 |
| shelfLife | 24 months |
| Storage conditions | Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the vial in the outer carton to protect from light. |
| Refrigerator Storage | Yes |
